A 58-year-old man with advanced lung cancer and bone metastases is on morphine 180 mg/day (oral) with inadequate pain control. He experiences breakthrough pain 4–5 times daily despite regular dosing. His renal function is normal (eGFR 78 mL/min/1.73 m²). Which of the following is the most appropriate next step in pain management?

Explanation

## Breakthrough Pain Management in Opioid-Tolerant Patients **Correct Answer: Switch to transdermal fentanyl 75 mcg/72 h and add immediate-release opioid for breakthrough pain** ### Rationale: This patient has **opioid-tolerant cancer pain** with inadequate control on 180 mg/day oral morphine. The standard approach for breakthrough pain in this setting involves: 1. **Conversion to long-acting formulation (transdermal fentanyl):** - Fentanyl 75 mcg/72 h is approximately equianalgesic to morphine 180 mg/day (using the 1:100 conversion ratio for opioid-naïve patients; for tolerant patients, conversion is individualized but fentanyl offers superior pharmacokinetics) - Transdermal delivery provides stable, continuous analgesia - Reduces fluctuations in serum levels that drive breakthrough pain 2. **Addition of immediate-release opioid for breakthrough pain:** - Typically 10–20% of total daily opioid dose given as IR formulation (e.g., morphine IR 15–30 mg, or fentanyl lozenge 200–400 mcg) - Addresses acute exacerbations without increasing baseline dosing - This is the **gold standard** per WHO analgesic ladder and cancer pain guidelines (ASCO, NCCN) 3. **Consideration of adjuvants:** - Neuropathic components (bone pain often has neuropathic features) may benefit from gabapentin, pregabalin, or duloxetine *in addition to* opioid optimization, not as replacement **Key Point:** The goal is NOT to increase baseline morphine dose further (risk of toxicity) but to optimize delivery kinetics and add targeted breakthrough coverage. --- ## Why Each Distractor Is Wrong: **Option 0: Increase oral morphine by 50% + NSAID** - Escalating oral morphine when already on 180 mg/day increases risk of constipation, cognitive impairment, and respiratory depression - NSAIDs are contraindicated or high-risk in advanced cancer (GI bleeding, renal compromise, platelet dysfunction) - Does NOT address the pharmacokinetic problem of breakthrough pain (fluctuating serum levels) **Option 2: Add gabapentin + reduce morphine by 25%** - Gabapentin is an adjuvant for neuropathic pain, NOT a substitute for opioid escalation in inadequately controlled cancer pain - Reducing morphine while pain is uncontrolled is counterintuitive and harmful - Gabapentin should be *added* to optimized opioid therapy, not used to replace it **Option 3: Initiate methadone monotherapy with abrupt morphine discontinuation** - Methadone is a valid alternative opioid but requires **slow, careful titration** (risk of QT prolongation, drug interactions, accumulation) - **Abrupt discontinuation of morphine** risks acute withdrawal and loss of analgesia - Methadone conversion is typically reserved for opioid-induced side effects or tolerance, not first-line for breakthrough pain - Requires ICU/high-dependency monitoring in many settings --- ## High-Yield Concepts: | Aspect | Detail | |--------|--------| | **Breakthrough pain definition** | Transient exacerbation of pain in opioid-tolerant patients on stable baseline therapy | | **First-line management** | Optimize long-acting formulation + add IR opioid (10–20% total daily dose) | | **Transdermal fentanyl advantage** | Steady-state levels, reduced fluctuation, lower GI side effects than oral morphine | | **Adjuvants** | Add (don't replace) for neuropathic/bone pain: gabapentin, pregabalin, duloxetine, NSAIDs (if safe) | | **Methadone role** | Rescue option for intolerable side effects or drug interactions; NOT first-line | **Clinical Pearl:** In cancer pain, the "ceiling" for opioid escalation is determined by toxicity, not efficacy. Once toxicity limits further dose increase, switch strategy (formulation, add adjuvants, consider interventional approaches like nerve blocks).